期刊
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
卷 22, 期 3, 页码 315-329出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2009.10.005
关键词
chronic myeloid leukaemia; interferon; randomized trials; stem cell dormancy
类别
Imatinib has revolutionized the therapy of chronic myeloid leukaemia. However the complete eradication of leukaemic stem cells is still a matter of discussion. interferon (IFN) has been used in the past with success. However the proportion of patients who achieved sustained complete cytogenetic response was small. Recently, in addition to its direct antineoplastic effect and immunomodulatory activity, IFN has been shown to stimulate the quiescent leukaemic stem cells. Thus there is now a rational for combining Imatinib and IFN. Large prospective phase III trials are in good progress to demonstrate in humans the usefullness of a combination therapy using Imatinib and IFN. (C) 2009 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据